Efficacy and Safety of Low-Dose Intravenous Dexamethasone and Parecoxib in prevention of post embolization syndrome

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20260608003

Enrollment

144

Registered

2026-06-08

Start date

2026-05-29

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

post-embolization syndrome TACE HCC HCC TACE Post-embolization syndrome Dexamethazone Parecoxib

Interventions

Low-dose IV dexamethasone (4 mg) combined with parecoxib (40 mg) 30 minutes before TACE,0.9% NSS intravenous same mL as Arm A 30 minutes before TACE

Experimental Drug,Placebo Comparator Drug

Arm A,Arm B

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. HCC with BCLC stage A to B 2. Cirrhosis CLP class A or B 3. Scheduled for TACE

Exclusion criteria

Exclusion criteria: 1. Uncontrolled diabetes 2. Active infection 3. Recent corticosteroid or NSAID use 4. Severe cardiovascular disease 5. Acute kidney injury 6. Recent gastrointestinal bleeding 7. Pregnancy 8. Drug allergy

Design outcomes

Primary

Measure	Time frame
incidence of post-embolization syndrome 48 hours percent	—

Secondary

Measure	Time frame
PES severity score 48 hours Score,Adverse event 48 hours percent	—

Countries

Thailand

Contacts

Public ContactChanunta Hongthanakorn

Bhumibol Adueyadej Hospital

rabbithap@yahoo.com025347000

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026